Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AdV-tk + Valacyclovir |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AdV-tk | Aglatimagene besadenovec|GliAtak|ProstAtak|Virafir | Aglatimagene besadenovec (AdV-tk) is an engineered adenoviral vector expressing the herpes simplex virus thymidine kinase that sensitizes tumor cells to therapy with acyclic guanosine analogues (PMID: 26843484, PMID: 30883662). | ||
Valacyclovir | Valtrex | Acicloftal|Virorax|CargosilBW-248U | Valacyclovir is the prodrug of acylovir, which is an antiviral agent that functions by inhibiting viral DNA polymerase (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | malignant glioma | not applicable | AdV-tk + Valacyclovir | Phase II | Actionable | In a Phase II trial, addition of AdV-tk and Valacyclovir to standard of care improved meidan overall survival (17.1 vs 13.5 months) compared to standard of care alone in patients with malignant glioma (PMID: 26843484). | 26843484 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01436968 | Phase III | Valacyclovir AdV-tk + Valacyclovir | Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Recruiting | USA | 1 |
NCT03131037 | Phase I | AdV-tk + Valacyclovir | Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT03004183 | Phase II | Pembrolizumab AdV-tk + Valacyclovir | SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC | Active, not recruiting | USA | 0 |
NCT01913106 | Phase Ib/II | AdV-tk + Valacyclovir | HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer | Recruiting | USA | 0 |
NCT02768363 | Phase II | AdV-tk + Valacyclovir Valacyclovir | Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | Active, not recruiting | USA | 1 |